|
|
|
| Therapeutic effect of Acarbose combined with Tongxinluo Capsules in coronary heart disease patients with impaired glucose tolerance |
| LI Hua-ping YIN Xiu-ying LIN Hai-yan |
| Department of Internal Medicine,the First People′s Hospital in Nankang District of Ganzhou City,Jiangxi Province,Ganzhou 341400,China |
|
|
|
|
Abstract ObjectiveTo analyze the therapeutic effect of Acarbose combined with Tongxinluo Capsules in coronary heart disease (CHD)patients with impaired glucose tolerance.MethodsA total of 120 patients with CHD complicated with impaired glucose tolerance admitted into our hospital were selected as research objects.They were divided into group A(n=33),group B(n=27),group C(n=31)and group D(n=29)according to the random number table method.The patients of the group A were treated with conventional treatment of secondary prevention of CHD,the patients of the group B were treated with Acarbose on the basis of the conventional treatment,the patients of the group C were treated with Tongxinluo Capsules on the basis of the conventional treatment and the patients of the group D were treated with Acarbose and Tongxinluo Capsules on the basis of the conventional treatment.The occurrence of cardiovascular events,results of coronary angiography and ratios of albumin-creatinine(UACR)within continuous half a year of follow up visits among the four groups were compared and analyzed.ResultsThe basic heart rate,body mass index,systolic pressure,diastolic blood pressure,blood lipid(total cholesterol,low density cholesterol and triglycerides),fasting blood-glucose and blood-glucose of 2 h after 75 g oral glucose,UACR and other general datas were compared of patients of the four groups,the differences were not statistically significant(P＞0.05).The results of coronary angiography were compared in four groups,the differences were not statistically significant(P＞0.05).After six months of follow-up,the UACR in group D was significantly lower than that of group B and C,and the differences were statistically significant(P＜0.05).The incidence of cardiovascular events in group A was higher than that in group B,C and D,and incidence of cardiovascular events in group D was lowest,the differences were statistically significant(P＜0.05).The incidence of cardiovascular events was compared in group B,C and D,the differences were not statistically significant(P＞0.05).ConclusionFor CHD patients with impaired glucose tolerance,combination of Acarbose and Tongxinluo Capsules can obtain a remarkable effect.The effect is better than single medication.It is beneficial to reduce the UACR level and reduce the incidence of adverse cardiovascular events,it is worth promoting the application.
|
|
|
|
|
|
| [1] |
邓丽立，程效雄.通心络胶囊联合阿托伐他汀钙片对冠心病患者血脂及炎症因子影响药理分析[J].辽宁中医药大学学报，2016，9（18）：190-192.
|
| [2] |
何丽霞，李卫东.通心络胶囊联合阿托伐他汀对冠心病患者血脂的影响[J].世界中医药，2015，9（10）：1344-1346.
|
| [3] |
李文书，王小芳，赵晓燕，等.二甲双胍对糖耐量减低冠心病患者血清炎症因子的影响[J].临床医学，2017，37（4）：48-50.
|
| [4] |
毛磊，赵洛沙，韩文杰，等.冠心病合并糖耐量减低患者动脉僵硬度的变化[J].中国卫生标准管理，2015，6（27）：136-138.
|
| [5] |
罗劲涛.老年糖耐量减低患者发生冠心病的高危因素[J].实用临床医学，2015，16（7）：24-26.
|
| [6] |
董学勤，安艳荣，吴志红，等.伴糖耐量减低的冠心病患者临床特征及病变特点分析[J].中国临床医生杂志，2016，44（1）：39-41.
|
| [7] |
段丽钦.糖耐量减低对冠心病患者支架植入术后预后的影响[D].大连：大连医科大学，2013.
|
| [8] |
董学勤，安艳荣，吴志红，等.伴糖耐量减低的冠心病患者临床特征及病变特点分析[J].中国临床医生杂志，2016，44（1）：39-41.
|
| [9] |
褚晓波.冠心病合并糖耐量异常患者冠状动脉病变的特点分析[J].中华危重病急救医学，2015，27（12）：1013-1014.
|
| [10] |
娄美萍.通心络胶囊治疗冠心病心绞痛临床疗效观察[J].海峡药学，2013，25（6）：141-142.
|
| [11] |
蒋宁.阿卡波糖对冠心病伴糖耐量异常患者氧化应激和血管内皮功能、心率变异性的影响[J].中国现代医学杂志，2015，25（28）：45-48.
|
| [12] |
刘书宇，王俊，叶沃若，等.伏格列波糖联合辛伐他汀对伴糖耐量减低老年冠心病患者血清脂联素、瘦素、内皮素的影响[J].现代中西医结合杂志，2016，25（35）：3964-3966.
|
| [13] |
陈青，卢敏，籍增洋，等.伏格列波糖对合并糖耐量减低老年冠心病患者早期干预治疗的临床研究[J].中国临床药理学杂志，2015，31（22）：2199-2201.
|
| [14] |
吴茂红，吕玲.糖耐量异常对冠心病患者氧化应激和血管内皮功能、心率变异性的影响及阿卡波糖的干预作用[J].中国动脉硬化杂志，2014，22（3）：287-292.
|
| [15] |
崔培霞，杨蓓，于磊峰，等.阿卡波糖对糖耐量减低患者血清CRP和血脂水平的影响[J].现代中西医结合杂志，2015，24（7）：759-761.
|
|
|
|
